Bivalirudin

Bivalirudin is a chemically synthesized peptide containing 20 amino acids. It directly inhibits thrombin and is sold as Angiomax, or Angiox outside the United States. Administration is intravenous in a hospital, commonly the cardiac catheterization laboratory; it is not an oral or home medicine.

Supporting references: direct thrombin inhibitors.

The template was hirudin, the natural anticoagulant protein that allows medicinal leeches to feed without the blood clotting. Bivalirudin is a shorter synthetic analog designed to bind thrombin at two sites. It was developed as a shorter-acting, more predictable alternative to heparin in heart procedures and first received FDA approval in 2000. Unlike the original leech protein, its inhibition is reversible and brief.

Supporting references: hirudin.

One end of bivalirudin occupies thrombin’s catalytic site and the other its fibrinogen-docking region, exosite 1. This prevents fibrinogen conversion to fibrin and thrombin-mediated platelet activation. It inhibits circulating and clot-bound thrombin, whereas heparin is less effective against the clot-bound form. Thrombin gradually cleaves the bound drug, restoring enzyme activity; the effect diminishes over roughly 25 minutes after stopping infusion.

Supporting references: Drugs.com.

HORIZONS-AMI studied 3,602 people with acute myocardial infarction undergoing angioplasty. Bivalirudin alone reduced major bleeding at 30 days and cardiac death compared with heparin plus a glycoprotein IIb/IIIa inhibitor.

Supporting references: HORIZONS-AMI trial.

The FDA approved Angiomax in 2000 for anticoagulation during coronary angioplasty. Later labeling included PCI patients with, or at risk of, heparin-induced thrombocytopenia. It prevents clot formation on catheters and freshly treated coronary arteries during angioplasty and stent placement. It is particularly useful when the immune-mediated reaction HIT makes heparin unsuitable. The clinical team administers and monitors it.

Bleeding is the main risk, even though trial major-bleeding rates were lower than with the specified heparin regimen. Back pain, nausea, hypotension and headache were also reported. HORIZONS-AMI found more acute stent thrombosis during the first 24 hours; that signal did not persist at 30 days. Adequate antiplatelet treatment and controlled hospital administration remain part of the clinical context.